MedTrace Logo

Piezo2-related Arthrogryposis & physiopathOLOgy 3

NCT07360574 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2026-01-22

No results posted yet for this study

Summary

Study type: Observational, non-interventional, single-center, descriptive study.

Goal of the study:

The goal of this observational study is to characterize the intensity, variability, and qualitative features of pain in patients with arthrogryposis multiplex congenita (AMC) caused by a gain-of-function mutation in PIEZO2. This population is rare and identified through the French national PARART registry (Pediatric and Adult Registry for patients with ARThrogryposis).

Population:

Participants are ≥10 years old, have a genetically confirmed gain-of-function PIEZO2 variant, and are registered in PARART. All procedures are conducted remotely; no onsite visit is required.

Main questions the study aims to answer:

* What is the intensity and day-to-day variability of pain over 14 consecutive days, measured with a Numerical Rating Scale (0-100)?
* What are the sensory qualities and anatomical distribution of pain in this population?
* How does this pain affect quality of life?
* What treatments (pharmacological or non-pharmacological) have been used, and how effective are they?

Study design:

There is no comparison group. The study is descriptive and aims to characterize the pain phenotype linked to PIEZO2 gain-of-function mutations.

What participants will do:

Participants will complete the following tasks remotely:

At Day 1:

Questionnaires:

* Saint-Antoine Pain Questionnaire (QDSA)
* SF-12
* EQ-5D-5L
* Pain monitoring: treatments used

For 14 consecutive days (Day 1 to Day 14), on a paper logbook:

* Daily self-reported Numerical Rating Scale (NRS, 0-100) for pain
* Daily body chart to document pain distribution

All data are collected through REDCap and a paper logbook. No clinical exam, biological sampling, or hospital visit is required.

The study duration for each participant is 14 days.

Conditions

  • Arthrogryposis Multiplex Congenita
  • Piezo2 Mutation Gain of Function

Sponsors & Collaborators

  • University Hospital, Grenoble

    lead OTHER

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-01
Primary Completion
2026-07-31
Completion
2026-07-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07360574 on ClinicalTrials.gov